GlassScriptPhysician profile
Nicholas C Ryser
NPI 1376193151
$3,859.40
in general payments reported to CMS, 2019-2025
26 companies · $689 in 2025
The $689 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $423 · 2022: $396 · 2023: $1,057 · 2024: $1,294 · 2025: $689.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,040.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,039.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,514.73 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $308.62 | 2021-2025 | Entyvio, Eohilia |
| Genzyme Corporation | $289.14 | 2022-2025 | |
| Celgene Corporation | $245.65 | 2022-2024 | Zeposia |
| Regeneron Healthcare Solutions, INC. | $207.93 | 2022-2025 | Dupixent |
| Intercept Pharmaceuticals, INC. | $181.02 | 2021-2024 | |
| Madrigal Pharmaceuticals | $154.37 | 2025 | Rezdiffra |
| Lilly USA, LLC | $127.80 | 2023-2024 | Omvoh |
| Janssen Scientific Affairs, LLC | $108.91 | 2021 | |
| Janssen Biotech, INC. | $101.43 | 2022-2025 | Tremfya, Stelara, Simponi Aria |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $97.86 | 2023-2024 | Xifaxan, Relistor |
| Ardelyx, INC. | $82.52 | 2023-2025 | Ibsrela |
| Pfizer INC. | $61.23 | 2023-2025 | |
| Nestle Healthcare Nutrition INC. | $58.35 | 2023 | |
| Ipsen Biopharmaceuticals, INC | $51.63 | 2024-2025 | Bylvay |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharmacosmos Therapeutics INC. | $45.70 | 2023 | Monoferric |
| Aimmune Therapeutics, INC. | $35.43 | 2024 | |
| Organon LLC | $34.58 | 2024 | |
| Phathom Pharmaceuticals, INC. | $27.53 | 2024-2025 | Voquezna |
| Celltrion USA INC. | $23.46 | 2025 | Vegzelma |
| Mallinckrodt Hospital Products INC. | $20.74 | 2025 | Terlivaz |
| Tersera Therapeutics LLC | $20.41 | 2025 | Xermelo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.25 | 2023 | Cyltezo |
| Digestive Care, INC. | $15.86 | 2024 | Pertzye |
| Shield Therapeutics INC | $13.73 | 2025 | |
| Qol Medical, LLC | $12.52 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicholas Ryser listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.